SearchDictionaryMobileLogin

Richard B Devereux Selected Research

Hypertension (High Blood Pressure)

08/2008Marked regional left ventricular heterogeneity in hypertensive left ventricular hypertrophy patients: a losartan intervention for endpoint reduction in hypertension (LIFE) cardiovascular magnetic resonance and echocardiographic substudy.
06/2008Left bundle branch block and cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension study.
04/2008Effects of losartan in women with hypertension and left ventricular hypertrophy: results from the Losartan Intervention for Endpoint Reduction in Hypertension Study.
04/2008Gender differences in left ventricular structure and function during antihypertensive treatment: the Losartan Intervention for Endpoint Reduction in Hypertension Study.
11/2007In-treatment resolution or absence of electrocardiographic left ventricular hypertrophy is associated with decreased incidence of new-onset diabetes mellitus in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Study.
09/2007Effect of hemoglobin levels on cardiovascular outcomes in patients with isolated systolic hypertension and left ventricular hypertrophy (from the LIFE study).
02/2007Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.
02/2007Left atrial size and risk of major cardiovascular events during antihypertensive treatment: losartan intervention for endpoint reduction in hypertension trial.
02/2007Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
01/2007Atenolol as a comparator in outcome trials in hypertension: a correct choice in the past, but not for the future?
08/2006N-terminal brain natriuretic peptide predicted cardiovascular events stronger than high-sensitivity C-reactive protein in hypertension: a LIFE substudy.
05/2006Association of hemoglobin delivery with left ventricular structure and function in hypertensive patients: Losartan Intervention for End Point Reduction in Hypertension Study.
03/2006Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study.
01/2006Electrocardiographic strain pattern and prediction of new-onset congestive heart failure in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study.
11/2005Targeting the renin-angiotensin system for the reduction of cardiovascular outcomes in hypertension: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
11/2005Aortic valve sclerosis and albuminuria predict cardiovascular events independently in hypertension: a losartan intervention for endpoint-reduction in hypertension (LIFE) substudy.
09/2005The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) study.
05/2005Opposite effects of losartan and atenolol on natriuretic peptides in patients with hypertension and left ventricular hypertrophy: a LIFE substudy.
04/2005Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) study.
04/2005Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy.
03/2005Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
03/2005Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
03/2005The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE study.
02/2005Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study.
01/2005Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study.
11/2004Losartan for the treatment of hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
09/2004Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial.
09/2004Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy.
09/2004Relation of impaired left ventricular filling to systolic midwall mechanics in hypertensive patients with normal left ventricular systolic chamber function: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study.
08/2004N-terminal pro-brain natriuretic peptide predicts cardiovascular events in patients with hypertension and left ventricular hypertrophy: a LIFE study.
06/2004Differences in left ventricular structure between black and white hypertensive adults: the Hypertension Genetic Epidemiology Network study.
05/2004QRS duration and QT interval predict mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention for Endpoint Reduction in Hypertension Study.
08/2003Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study.
04/2003An analysis of cholesterol control and statin use in the Losartan Intervention for Endpoint Reduction in Hypertension Study.
04/2003Regression of left ventricular hypertrophy after treatment of hypertension: comparison of directed M-echocardiography with magnetic resonance imaging in quantification of serial mass changes.
12/2002Change of left ventricular geometric pattern after 1 year of antihypertensive treatment: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
09/2002Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.
09/2002Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study.
09/2002Is cardiovascular remodeling in patients with essential hypertension related to more than high blood pressure? A LIFE substudy. Losartan Intervention For Endpoint-Reduction in Hypertension.
07/2002Progressive hypertrophy regression with sustained pressure reduction in hypertension: the Losartan Intervention For Endpoint Reduction study.
03/2002Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
03/2002Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
03/2002Change in diastolic left ventricular filling after one year of antihypertensive treatment: The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study.
03/2002Correlates of left atrial size in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study.

Articles by Research Topic

Disease

44Hypertension (High Blood Pressure)
08/2008 - 03/2002
26Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left)
08/2008 - 02/2002
4Atrial Fibrillation
08/2007 - 03/2005
4Stroke (Strokes)
02/2007 - 01/2005
3Albuminuria
11/2005 - 09/2004
2Atherosclerosis (Atheroma)
04/2008 - 05/2007
2Diabetes Mellitus
11/2007 - 03/2006
2Sclerosis
11/2005 - 10/2004
1Carotid Artery Diseases
08/2008
1Coronary Artery Disease (Coronary Atherosclerosis)
08/2008
1Bundle-Branch Block (Fascicular Block)
06/2008
1Myocardial Infarction
11/2007
1Marfan Syndrome (Marfan's Syndrome)
10/2007
1Brain Ischemia (Cerebral Ischemia)
05/2007
1Systemic Lupus Erythematosus (Libman-Sacks Disease)
12/2006
1Obesity
06/2006
1Heart Failure
01/2006
1Cardiomegaly (Heart Hypertrophy)
01/2005
1Vascular Diseases (Vascular Disease)
08/2003
1Cardiovascular Diseases (Cardiovascular Disease)
03/2003
1Hypertrophy
07/2002
1Heart Valve Diseases (Valvular Heart Disease)
06/2002

Drug/Important Bio-Agent (IBA)

44Losartan (Cozaar)FDA Link
08/2008 - 02/2002
18Atenolol (Tenormin)FDA LinkGeneric
10/2007 - 02/2002
3AngiotensinsIBA
08/2007 - 11/2005
2Angiotensin Receptors (Angiotensin II Receptor)IBA
10/2007 - 03/2005
2Hemoglobins (Hemoglobin)IBA
09/2007 - 05/2006
2Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA
09/2006 - 11/2005
2Brain Natriuretic Peptide (Natrecor)FDA Link
08/2006 - 08/2004
1Omega-3 Fatty Acids (Omega 3 Fatty Acids)FDA Link
08/2008
1LDL CholesterolIBA
04/2008
1CalciumIBA
05/2007
1Antiphospholipid AntibodiesIBA
12/2006
1C-Reactive ProteinIBA
08/2006
1Insulin (Novolin)FDA Link
06/2006
1CalcineurinIBA
10/2005
1Aspirin (Acetylsalicylic Acid)FDA LinkGeneric
09/2005
1Natriuretic PeptidesIBA
05/2005
1hydroquinone (Black and White)FDA Link
06/2004
1CholesterolIBA
04/2003
1Fibrinogen (Factor I)IBA
03/2003
1Appetite Depressants (Anorectics)IBA
06/2002
1CreatinineIBA
02/2002

Therapy/Procedure

1Angioplasty (Angioplasties)
11/2007
1Aftercare (After-Treatment)
04/2003